Actavis Starts its Business in Ireland
Entering the Irish market last week, Actavis plans to create up to 25 new local jobs over the next five years and to launch more than 120 generic drugs in Ireland, with the potential to save millions of euro off the country’s annual health bill.
The new roles Actavis will create are in addition to 11 corporate employees currently based in Ireland.
“Over the next five years, we plan to rapidly expand our offering in Ireland in all channels-hospital-specific, prescription, and over the counter medicines,” says Actavis Ireland Managing Director Tony Hynds.
The arrival of Actavis into the Irish market, Hynds said, came at a time when the country was struggling to meet the rapidly rising cost of
healthcare.“In Ireland, Actavis has established a team with deep expertise in the local industry, people who understand the nature of the market here, and has given them the backing of a vast global product pipeline,” Hynds added.
Actavis launched a generic cancer treatment drug, Gemcitabine, on the Irish market last Monday. It was made available for prescription from 9th March, on day one when the patent for Gemcitabine expired in Ireland.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
